2257.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 01:43):

Stats
Today's Volume	4.25M
Average Volume	3.08M
Market Cap	532.84M
EPS	HKD0 ( 2023-08-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.750
ATR14	HKD0.0150 (0.25%)

Volume Correlation

Long: 0.06 (neutral)

Short: 0.00 (neutral)

Signal:(48.439) Neutral

Sirnaomics Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sirnaomics Ltd. Correlation - Currency/Commodity

-0.17
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.71
( moderate )

0.53
( weak )

-0.13
( neutral )

Sirnaomics Ltd. Financials

Annual	2023
Revenue:	HKD40 000.00
Gross Profit:	HKD40 000.00 (100.00 %)
EPS:	HKD-1.030

Q3	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Q2	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Q1	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Financial Reports:

No articles found.

Sirnaomics Ltd.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.